János Wölfling

János Wölfling

Auto-generated profile, based on publicly available information

János Wölfling

Department of Organic Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
Éva FrankÉva Frank
Éva Frank
ZMZoltán Mucsi
Zoltán Mucsi
IZIstvan Zupko
Istvan Zupko
BRBorbála Réthy
Borbála Réthy
GFGeorge Falkay
George Falkay
JWJános Wölfling
János Wölfling

1 January 2013 in Steroids
Verified
Journal Article
Closed access
ÁBÁgnes Berényi
Ágnes Berényi
RMRenáta Minorics
Renáta Minorics
ZIZoltán Iványi
Zoltán Iványi
IOImre Ocsovszki
Imre Ocsovszki
EDEszter Ducza
Eszter Ducza
IZIstvan Zupko
Istvan Zupko

1 April 2012 in Steroids
Verified
Journal Article
Closed access
ZIZoltán Iványi
Zoltán Iványi
NSNikoletta Szabó
Nikoletta Szabó
JHJudit Huber
Judit Huber
JWJános Wölfling
János Wölfling
IZIstvan Zupko
Istvan Zupko
GSGyula Schneider
Gyula Schneider

1 January 2013 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JKJános P Kósa
János P Kósa
PHPéter Horváth
Péter Horváth
JWJános Wölfling
János Wölfling
DKDóra Kovács
Dóra Kovács
BBBernadett Balla
Bernadett Balla
PLPéter Lakatos
Péter Lakatos
The effects of vitamin D3 have been investigated on various tumors, including colorectal cancer (CRC). 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the enzyme that inactivates the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered to be the main enzyme determining the biological half-life of 1,25-D3. During colorectal carcinogenesis, the expression and concentration of CYP24A1 increases significantly, suggesting that this phenomenon could be responsible for the proposed efficacy of 1,25-D3 in the treatment of CRC. The aim of this study was to investigate the anti-tumor effects of vitamin D3 on the human CRC cell line Caco-2 after inhibition of the cytochrome P450 component of CYP24A1 activity. We examined the expression of CYP24A1 mRNA and the effects of 1,25-D3 on the cell line Caco-2 after inhibition of CYP24A1. Cell viability and proliferation were determined by means of sulforhodamine-B staining and bromodeoxyuridine incorporation, respectively, while cytotoxicity was estimated via the lactate dehydrogenase content of the cell culture supernatant. CYP24A1 expression was measured by real-time reverse transcription polymerase chain reaction. A number of tetralone compounds were synthesized to investigate their CP24A1 inhibitory activity. In response to 1,25-D3, CYP24A1 mRNA expression was enhanced significantly, in a time- and dose-dependent manner. Caco-2 cell viability and proliferation were not influenced by the administration of 1,25-D3 alone, but were markedly reduced by co-administration of 1,25-D3 and KD-35, a CYP24A1-inhibiting tetralone. Our data suggest that the mechanism of action of co-administered KD-35 and 1,25-D3 does not involve a direct cytotoxic effect, but rather the inhibition of cell proliferation. These findings demonstrate that the selective inhibition of CYP24A1 by compounds such as KD-35 may be a new approach for enhancement of the anti-tumor effect of 1,25-D3 on CRC.

1 September 2004 in Current Organic Chemistry
Verified
Journal Article
Closed access
PDF file
GSGyula Schneider
Gyula Schneider
JWJanos Wolfling
Janos Wolfling
The medical application of cardenolides and bufadienolides is associated with a high risk, due to their toxicity and the small difference between the therapeutic and toxic doses. In the past few years, increasing attention has been paid to the mechanism of cardiotonic action and the synthesis of cardenolide and bufadienolide analogs which are expected to have better therapeutic indices. A cardenolide analog in which the lactone ring is replaced by a nitrogen-containing unsaturated heterocycle was found to be almost as active as the parent compound. A knowledge of the activity of such compounds would contribute to the question of the structural requirements for a heterocyclic substitutent. Pharmacological examinations have shown that the cardiotonic activity of the 17β-exoheterocyclic steroids is weaker than that of the parent compound, although the ratio of the therapeutic effect to the toxic effect is favorable. Besides cardiotonic activity, a large number of exo-heterocyclic steroids display a potential as inhibitors of human cytochrome P450 17α, the enzyme responsible for the conversion of C21 steroids to the related C19 steroids (androgens). This is a potential approach for the therapeutic treatment of this disease, which frequently exhibits an androgen dependence. This review deals with recent studies of the synthesis of modified cardenolides which are expected to have better cardiotonic activities, and with the synthesis of steroids with a variety of heterocycles at C-17 which have been tested against P45017α.

1 September 2011 in Steroids
Verified
Journal Article
Closed access
Éva FrankÉva Frank
Éva Frank
JMJudit Molnár
Judit Molnár
IZIstvan Zupko
Istvan Zupko
ZKZalán Kádár
Zalán Kádár
JWJános Wölfling
János Wölfling